Dexamethasone, pro‐resolving lipid mediators and resolution of inflammation in COVID‐19

Dexamethasone, pro‐resolving lipid mediators and resolution of inflammation in COVID‐19:

Abstract

Coronavirus disease‐19 (COVID‐19) is a new disease caused by SARS‐CoV‐2. Since the beginning of 2020, it has become one of the main challenges of our times, causing a high incidence of severe pneumonia, acute respiratory distress syndrome (ARDS), multiorgan failure and death¹. At the root of COVID‐19 lies the sudden development of ‘cytokine storms’, hyper‐inflammatory responses involving the release of pro‐inflammatory cytokines (e.g., TNF, IL‐6, IL‐1, IL‐8, and MCP‐1) that impair the gas exchange function of the lung and lead in select patients, mostly with underlying comorbidities, to multiorgan failure and death.